Multi-cancer blood tests coming to UK GP surgeries
UK government launches the STRIDE-RCT trial for over 20,000 patients aged 45 and over to evaluate a new multi-cancer blood test at local GP practices.
Stock photo for illustration only, not from the actual event
- UK introduces blood tests for over 20,000 patients at local clinics
- Focuses on hard-to-detect abdominal cancers like liver and ovarian
- Government-funded trial is led by the University of Birmingham
Healthcare providers in England are preparing to introduce a novel blood test capable of screening multiple cancers directly at general practice surgeries in the near future. The primary objective is to detect abdominal cancers that are notoriously difficult to diagnose in their early stages, such as liver, ovarian, and pancreatic cancers, which are typically identified only after the disease has already spread extensively.
The diagnostic procedure searches for specific proteins or circulating DNA fragments in the bloodstream that serve as warning signs of malignancy. These findings will assist physicians in determining which patients presenting with vague symptoms require immediate, in-depth clinical investigations. Titled the STRIDE-RCT trial, this research specifically targets a wide array of malignancies including bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct, gallbladder, ovarian, endometrial, kidney, bladder, and prostate cancers.
Stock photo for illustration only, not from the actual event
Backed by government funding and spearheaded by researchers from the University of Birmingham, the trial will involve more than 20,000 patients aged 45 and older who report persistent symptoms like abdominal pain or bloating. Participants will provide one or two tubes of blood during routine appointments at their local doctor's office. Scientists will then examine the samples for molecular markers of cancer and potentially map the tumor's location within the body if detected.
Health officials have emphasized that a positive result does not automatically confirm cancer, nor does a negative test guarantee a complete all-clear. This initiative arrives as official figures show approximately 71,000 individuals in England are diagnosed each year with pancreatic, stomach, liver, ovarian, or bowel cancer, with nearly 35,000 succumbing to these illnesses annually. Catching the disease earlier provides patients with significantly higher chances of successful treatment and long-term survival.
The integration of Multi-Cancer Early Detection (MCED) blood tests into primary care represents a critical milestone in modern medicine. Because hard-to-diagnose abdominal cancers often present with non-specific early symptoms, patients frequently present at advanced stages. If this trial demonstrates sufficient accuracy for widespread National Health Service (NHS) adoption, it could fundamentally transform cancer screening protocols and save countless lives globally.
"GPs have long needed better tools to help them navigate that uncertainty by identifying which patients require further testing and this trial in England is an important step towards addressing that need."
Michelle Mitchell, Cancer Research UK
Health Secretary Yvette Cooper expressed her hope that straightforward blood tests like these will enable clinicians to identify patients requiring urgent investigations much sooner. Michelle Mitchell from Cancer Research UK echoed this sentiment, noting that primary care physicians have long awaited such innovative tools to reduce diagnostic uncertainty.
Source: BBC Health
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment